Freenome raises US $270M for cancer tests



News : Freenome, a developer of early cancer detection diagnostics that work with a routine blood draw, announced its largest funding round to date in an oversubscribed $270 million Series C round. Bain Capital Life Sciences and Perceptive Advisors led the financing for the South San Francisco-based company, which has raised more than $500 million.

Freenome raises US $270M for cancer tests full

Desktop Metal, a developer of systems for metal and carbon fiber 3D printing, is the latest heavily funded private company to plan a public market debut. The Massachusetts-based unicorn said it plans to become publicly listed through a merger with a special purpose acquisition company (SPAC) at an initial equity value of up to $2.5 billion.

Kinnate Biopharma announced that it has closed a $98 million Series C round led by RA Capital Management. The San Diego-based company is discovering and developing small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.
 

Freenome raises US $270M for cancer tests